NVSEF - Novartis Q2 Earnings Preview: Positive Fundamental Trends Should Continue

2024-07-15 10:09:03 ET

Summary

• Novartis AG will report second quarter results this week.
• The company should report another strong quarter, with growth led by key products such as Entresto, Kesimpta, Kisqali, Cosentyx, and Leqvio.
• I expect a modest revenue and EPS beat, with NVS maintaining the full-year guidance for both revenues and core operating income.
• No major milestones are expected, but Novartis should highlight the recent successful late-stage trial updates.

Novartis AG ( NVS ) recovered from the brief pullback earlier this year and reached new all-time highs. The company will report second quarter results this week. Based on the year-to-date execution and developments, I would expect a continuation of positive fundamental trends, and I am maintaining the positive outlook on the stock that is consistent with my October 2023 upgrade article. There, I outlined how a new and improved Novartis is well-positioned to create shareholder value....

For further details see: